HLA-DO is a negative modulator of HLA-DM-mediated MHC class II peptide loading

Class II molecules of the major histocompatibility complex become loaded with antigenic peptides after dissociation of invariant chainderived peptides (CLIP) from the peptide-binding groove. The human leukocyte antigen (HLA)-DM is a prerequisite for this process, which takes place in specialised int...

Full description

Saved in:
Bibliographic Details
Published in:Current biology Vol. 7; no. 12; p. 950
Main Authors: van Ham, S M, Tjin, E P, Lillemeier, B F, Grüneberg, U, van Meijgaarden, K E, Pastoors, L, Verwoerd, D, Tulp, A, Canas, B, Rahman, D, Ottenhoff, T H, Pappin, D J, Trowsdale, J, Neefjes, J
Format: Journal Article
Language:English
Published: England 01.12.1997
Subjects:
ISSN:0960-9822
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Class II molecules of the major histocompatibility complex become loaded with antigenic peptides after dissociation of invariant chainderived peptides (CLIP) from the peptide-binding groove. The human leukocyte antigen (HLA)-DM is a prerequisite for this process, which takes place in specialised intracellular compartments. HLA-DM catalyses the peptide-exchange process, simultaneously functioning as a peptide 'editor', favouring the presentation of stably binding peptides. Recently, HLA-DO, an unconventional class II molecule, has been found associated with HLA-DM in B cells, yet its function has remained elusive. The function of the HLA-DO complex was investigated by expression of both chains of the HLA-DO heterodimer (either alone or fused to green fluorescent protein) in human Mel JuSo cells. Expression of HLA-DO resulted in greatly enhanced surface expression of CLIP via HLA-DR3, the conversion of class II complexes to the SDS-unstable phenotype and reduced antigen presentation to T-cell clones. Analysis of peptides eluted from HLA-DR3 demonstrated that CLIP was the major peptide bound to class II in the HLA-DO transfectants. Peptide exchange assays in vitro revealed that HLA-DO functions directly at the level of class II peptide loading by inhibiting the catalytic action of HLA-DM. HLA-DO is a negative modulator of HLA-DM. By stably associating with HLA-DM, the catalytic action of HLA-DM on class II peptide loading is inhibited. HLA-DO thus affects the peptide repertoire that is eventually presented to the immune system by MHC class II molecules.
AbstractList Class II molecules of the major histocompatibility complex become loaded with antigenic peptides after dissociation of invariant chainderived peptides (CLIP) from the peptide-binding groove. The human leukocyte antigen (HLA)-DM is a prerequisite for this process, which takes place in specialised intracellular compartments. HLA-DM catalyses the peptide-exchange process, simultaneously functioning as a peptide 'editor', favouring the presentation of stably binding peptides. Recently, HLA-DO, an unconventional class II molecule, has been found associated with HLA-DM in B cells, yet its function has remained elusive. The function of the HLA-DO complex was investigated by expression of both chains of the HLA-DO heterodimer (either alone or fused to green fluorescent protein) in human Mel JuSo cells. Expression of HLA-DO resulted in greatly enhanced surface expression of CLIP via HLA-DR3, the conversion of class II complexes to the SDS-unstable phenotype and reduced antigen presentation to T-cell clones. Analysis of peptides eluted from HLA-DR3 demonstrated that CLIP was the major peptide bound to class II in the HLA-DO transfectants. Peptide exchange assays in vitro revealed that HLA-DO functions directly at the level of class II peptide loading by inhibiting the catalytic action of HLA-DM. HLA-DO is a negative modulator of HLA-DM. By stably associating with HLA-DM, the catalytic action of HLA-DM on class II peptide loading is inhibited. HLA-DO thus affects the peptide repertoire that is eventually presented to the immune system by MHC class II molecules.
Class II molecules of the major histocompatibility complex become loaded with antigenic peptides after dissociation of invariant chainderived peptides (CLIP) from the peptide-binding groove. The human leukocyte antigen (HLA)-DM is a prerequisite for this process, which takes place in specialised intracellular compartments. HLA-DM catalyses the peptide-exchange process, simultaneously functioning as a peptide 'editor', favouring the presentation of stably binding peptides. Recently, HLA-DO, an unconventional class II molecule, has been found associated with HLA-DM in B cells, yet its function has remained elusive.BACKGROUNDClass II molecules of the major histocompatibility complex become loaded with antigenic peptides after dissociation of invariant chainderived peptides (CLIP) from the peptide-binding groove. The human leukocyte antigen (HLA)-DM is a prerequisite for this process, which takes place in specialised intracellular compartments. HLA-DM catalyses the peptide-exchange process, simultaneously functioning as a peptide 'editor', favouring the presentation of stably binding peptides. Recently, HLA-DO, an unconventional class II molecule, has been found associated with HLA-DM in B cells, yet its function has remained elusive.The function of the HLA-DO complex was investigated by expression of both chains of the HLA-DO heterodimer (either alone or fused to green fluorescent protein) in human Mel JuSo cells. Expression of HLA-DO resulted in greatly enhanced surface expression of CLIP via HLA-DR3, the conversion of class II complexes to the SDS-unstable phenotype and reduced antigen presentation to T-cell clones. Analysis of peptides eluted from HLA-DR3 demonstrated that CLIP was the major peptide bound to class II in the HLA-DO transfectants. Peptide exchange assays in vitro revealed that HLA-DO functions directly at the level of class II peptide loading by inhibiting the catalytic action of HLA-DM.RESULTSThe function of the HLA-DO complex was investigated by expression of both chains of the HLA-DO heterodimer (either alone or fused to green fluorescent protein) in human Mel JuSo cells. Expression of HLA-DO resulted in greatly enhanced surface expression of CLIP via HLA-DR3, the conversion of class II complexes to the SDS-unstable phenotype and reduced antigen presentation to T-cell clones. Analysis of peptides eluted from HLA-DR3 demonstrated that CLIP was the major peptide bound to class II in the HLA-DO transfectants. Peptide exchange assays in vitro revealed that HLA-DO functions directly at the level of class II peptide loading by inhibiting the catalytic action of HLA-DM.HLA-DO is a negative modulator of HLA-DM. By stably associating with HLA-DM, the catalytic action of HLA-DM on class II peptide loading is inhibited. HLA-DO thus affects the peptide repertoire that is eventually presented to the immune system by MHC class II molecules.CONCLUSIONSHLA-DO is a negative modulator of HLA-DM. By stably associating with HLA-DM, the catalytic action of HLA-DM on class II peptide loading is inhibited. HLA-DO thus affects the peptide repertoire that is eventually presented to the immune system by MHC class II molecules.
Author Verwoerd, D
Canas, B
Rahman, D
Ottenhoff, T H
van Ham, S M
Tjin, E P
Neefjes, J
Pastoors, L
Trowsdale, J
Lillemeier, B F
van Meijgaarden, K E
Grüneberg, U
Pappin, D J
Tulp, A
Author_xml – sequence: 1
  givenname: S M
  surname: van Ham
  fullname: van Ham, S M
  email: vanham@nki.nl
  organization: Department of Cellular Biochemistry, The Netherlands Cancer Institute, Plesmanlaan 121, 1066, CX Amsterdam, The Netherlands. vanham@nki.nl
– sequence: 2
  givenname: E P
  surname: Tjin
  fullname: Tjin, E P
– sequence: 3
  givenname: B F
  surname: Lillemeier
  fullname: Lillemeier, B F
– sequence: 4
  givenname: U
  surname: Grüneberg
  fullname: Grüneberg, U
– sequence: 5
  givenname: K E
  surname: van Meijgaarden
  fullname: van Meijgaarden, K E
– sequence: 6
  givenname: L
  surname: Pastoors
  fullname: Pastoors, L
– sequence: 7
  givenname: D
  surname: Verwoerd
  fullname: Verwoerd, D
– sequence: 8
  givenname: A
  surname: Tulp
  fullname: Tulp, A
– sequence: 9
  givenname: B
  surname: Canas
  fullname: Canas, B
– sequence: 10
  givenname: D
  surname: Rahman
  fullname: Rahman, D
– sequence: 11
  givenname: T H
  surname: Ottenhoff
  fullname: Ottenhoff, T H
– sequence: 12
  givenname: D J
  surname: Pappin
  fullname: Pappin, D J
– sequence: 13
  givenname: J
  surname: Trowsdale
  fullname: Trowsdale, J
– sequence: 14
  givenname: J
  surname: Neefjes
  fullname: Neefjes, J
BackLink https://www.ncbi.nlm.nih.gov/pubmed/9382849$$D View this record in MEDLINE/PubMed
BookMark eNo9kE1LAzEYhHOo1Lb6Ewo5iR5W89Vsciy12kJrD-p5ySZvSmR3s252Bf-9RYungeGZgZkpGjWxAYTmlNxTQuXDK9GSZFoxdkvkHSGCioyP0OTfvkTTlD4IoUxpOUZjzRVTQk_Qy2a3zB4POCRscANH04cvwHV0Q2X62OHo8S-xz2pwwfTg8H6zwrYyKeHtFrfQ9sEBrqJxoTleoQtvqgTXZ52h96f122qT7Q7P29Vyl1muRJ85lxvuF5TmkuRc0lJYC8JqRr0XTkOuSr1wynrLpQdupaIKCC3z3J5y3rIZuvnrbbv4OUDqizokC1VlGohDKnItONOUnMD5GRzK04Ki7UJtuu_ifAD7Aa3fXBk
CitedBy_id crossref_primary_10_1111_j_1365_3083_2009_02301_x
crossref_primary_10_1016_j_it_2016_08_010
crossref_primary_10_4049_jimmunol_176_6_3536
crossref_primary_10_1093_emboj_cdg591
crossref_primary_10_1002_path_2455
crossref_primary_10_1016_j_coi_2004_11_003
crossref_primary_10_1007_s00251_018_1082_2
crossref_primary_10_1189_jlb_0105020
crossref_primary_10_4049_jimmunol_167_9_5167
crossref_primary_10_1242_jcs_112_6_785
crossref_primary_10_1002_eji_200737444
crossref_primary_10_1083_jcb_200510071
crossref_primary_10_1189_jlb_0410237
crossref_primary_10_1038_s41467_017_02777_6
crossref_primary_10_1128_JVI_05151_11
crossref_primary_10_1073_pnas_2034960100
crossref_primary_10_1016_S0952_7915_98_80032_0
crossref_primary_10_3389_fimmu_2019_01033
crossref_primary_10_1016_j_immuni_2017_07_013
crossref_primary_10_1016_S0161_5890_98_00061_3
crossref_primary_10_1016_j_humimm_2004_01_005
crossref_primary_10_1186_s12864_017_3760_0
crossref_primary_10_1016_j_imbio_2012_12_003
crossref_primary_10_1073_pnas_1004664107
crossref_primary_10_1091_mbc_e03_08_0614
crossref_primary_10_4049_jimmunol_1901409
crossref_primary_10_1016_j_coi_2011_11_004
crossref_primary_10_4049_jimmunol_168_4_1780
crossref_primary_10_4049_jimmunol_1003137
crossref_primary_10_1074_jbc_M306688200
crossref_primary_10_1111_tan_12538
crossref_primary_10_1073_pnas_0500853102
crossref_primary_10_1016_j_yexcr_2006_01_033
crossref_primary_10_4049_jimmunol_1300929
crossref_primary_10_1084_jem_20012066
crossref_primary_10_1034_j_1399_0039_2002_600504_x
crossref_primary_10_1371_journal_pbio_3000590
crossref_primary_10_1182_blood_2011_12_399311
crossref_primary_10_1083_jcb_200506083
crossref_primary_10_1111_j_1600_065X_1999_tb01370_x
crossref_primary_10_1111_j_1600_065X_1999_tb01393_x
crossref_primary_10_4049_jimmunol_178_3_1488
crossref_primary_10_7717_peerj_5228
crossref_primary_10_1002__SICI_1521_4141_199902_29_02_571__AID_IMMU571_3_0_CO_2_E
crossref_primary_10_1111_iji_12490
crossref_primary_10_4049_jimmunol_0803218
crossref_primary_10_1038_s41598_019_50111_5
crossref_primary_10_1091_mbc_e04_04_0275
crossref_primary_10_1034_j_1399_0039_2002_590608_x
crossref_primary_10_1016_j_immuni_2005_01_006
crossref_primary_10_1016_j_humimm_2013_05_010
crossref_primary_10_1038_nsmb_2484
crossref_primary_10_1074_jbc_273_42_27557
crossref_primary_10_3389_fimmu_2021_734282
crossref_primary_10_1111_j_1600_065X_1999_tb01366_x
crossref_primary_10_1002_immu_200310015
crossref_primary_10_1016_j_humimm_2004_10_002
crossref_primary_10_4049_jimmunol_167_3_1371
crossref_primary_10_4049_jimmunol_167_2_884
crossref_primary_10_1093_intimm_11_1_99
crossref_primary_10_4049_jimmunol_2100061
crossref_primary_10_1002_eji_200323853
crossref_primary_10_1172_JCI40220
crossref_primary_10_1111_j_1600_065X_1999_tb01368_x
crossref_primary_10_1016_S0952_7915_99_00057_6
crossref_primary_10_1111_j_1600_065X_1999_tb01371_x
crossref_primary_10_4049_jimmunol_161_7_3282
crossref_primary_10_1111_j_1365_2141_2009_07625_x
crossref_primary_10_4049_jimmunol_1002656
crossref_primary_10_1242_jcs_061135
crossref_primary_10_1016_j_coi_2020_05_007
crossref_primary_10_1111_j_0105_2896_2005_00302_x
crossref_primary_10_1002__SICI_1521_4141_199902_29_02_660__AID_IMMU660_3_0_CO_2_I
crossref_primary_10_1038_nsmb_2460
crossref_primary_10_1111_j_1365_2567_2008_02984_x
crossref_primary_10_1146_annurev_immunol_18_1_113
crossref_primary_10_1016_S1074_7613_00_80620_2
crossref_primary_10_4049_jimmunol_171_5_2374
crossref_primary_10_1093_emboj_19_5_882
crossref_primary_10_1099_jgv_0_001034
crossref_primary_10_4049_jimmunol_1400964
crossref_primary_10_1371_journal_ppat_1012306
crossref_primary_10_1002_cbic_201200497
crossref_primary_10_1034_j_1399_0039_2002_600610_x
crossref_primary_10_1084_jem_20012059
crossref_primary_10_1096_fasebj_14_10_1265
crossref_primary_10_4049_jimmunol_165_3_1410
crossref_primary_10_1002_1521_4141_200010_30_10_2871__AID_IMMU2871_3_0_CO_2_B
crossref_primary_10_1074_jbc_M005112200
crossref_primary_10_1084_jem_191_7_1127
crossref_primary_10_1016_j_coi_2013_11_005
crossref_primary_10_4049_jimmunol_2300213
crossref_primary_10_4049_jimmunol_171_5_2331
crossref_primary_10_1038_s41598_019_50455_y
crossref_primary_10_1111_j_1365_2567_2010_03282_x
crossref_primary_10_1038_sj_emboj_7601945
crossref_primary_10_1007_BF02786487
crossref_primary_10_4049_jimmunol_1200993
crossref_primary_10_1111_imr_12003
crossref_primary_10_1073_pnas_1113966109
crossref_primary_10_1002_eji_200323472
crossref_primary_10_1016_S0952_7915_01_00294_1
crossref_primary_10_1016_j_ccr_2004_05_016
crossref_primary_10_1098_rsob_160165
crossref_primary_10_4049_jimmunol_2100650
crossref_primary_10_1038_sj_emboj_7601791
crossref_primary_10_1074_jbc_M302399200
crossref_primary_10_4049_jimmunol_176_6_3548
crossref_primary_10_4049_jimmunol_173_3_1549
crossref_primary_10_1016_S0960_9822_98_70988_1
crossref_primary_10_4049_jimmunol_167_12_6849
crossref_primary_10_1017_erm_2012_9
crossref_primary_10_1006_smim_1999_0197
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/S0960-9822(06)00414-3
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Biology
ExternalDocumentID 9382849
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
--K
-DZ
-~X
0R~
0SF
1RT
1~5
2WC
4.4
457
4G.
53G
5GY
62-
6I.
6J9
7-5
AACTN
AAEDT
AAEDW
AAFTH
AAFWJ
AAIKJ
AAKRW
AALRI
AAMRU
AAQXK
AAVLU
AAXUO
ABJNI
ABMAC
ABVKL
ABWVN
ACGFO
ACGFS
ACRPL
ADBBV
ADEZE
ADMUD
ADNMO
ADVLN
AEFWE
AENEX
AEXQZ
AFTJW
AGHFR
AGHSJ
AGKMS
AGUBO
AHHHB
AITUG
AKAPO
AKRWK
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ASPBG
AVWKF
AZFZN
BAWUL
CAG
CGR
COF
CS3
CUY
CVF
DIK
DU5
E3Z
EBS
ECM
EIF
EJD
F5P
FCP
FDB
FGOYB
FIRID
HZ~
IHE
IXB
J1W
JIG
LX5
M3Z
M41
NCXOZ
NPM
O-L
O9-
OK1
OZT
P2P
R2-
RCE
ROL
RPZ
SCP
SDG
SES
SSZ
TR2
UHS
XPP
ZGI
7X8
AAYWO
ABDGV
ACVFH
ADCNI
AEUPX
AFPUW
AGQPQ
AIGII
AKBMS
AKYEP
APXCP
EFKBS
ID FETCH-LOGICAL-c384t-dd7a3f5117607361b4cce4c921ff4d9e78b95d8cfc36fe3c6818e01b77ca3ffc2
IEDL.DBID 7X8
ISICitedReferencesCount 144
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=10.1016/s0960-9822(06)00414-3&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 0960-9822
IngestDate Thu Oct 02 12:05:44 EDT 2025
Thu Jan 02 23:02:06 EST 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 12
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c384t-dd7a3f5117607361b4cce4c921ff4d9e78b95d8cfc36fe3c6818e01b77ca3ffc2
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink http://www.cell.com/article/S0960982206004143/pdf
PMID 9382849
PQID 79432910
PQPubID 23479
ParticipantIDs proquest_miscellaneous_79432910
pubmed_primary_9382849
PublicationCentury 1900
PublicationDate 1997-Dec-01
19971201
PublicationDateYYYYMMDD 1997-12-01
PublicationDate_xml – month: 12
  year: 1997
  text: 1997-Dec-01
  day: 01
PublicationDecade 1990
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Current biology
PublicationTitleAlternate Curr Biol
PublicationYear 1997
SSID ssj0012896
Score 1.9532427
Snippet Class II molecules of the major histocompatibility complex become loaded with antigenic peptides after dissociation of invariant chainderived peptides (CLIP)...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 950
SubjectTerms Amino Acid Sequence
Antigen Presentation
Antigens, Differentiation, B-Lymphocyte - metabolism
Cell Line
Histocompatibility Antigens Class II - metabolism
HLA-D Antigens - genetics
HLA-D Antigens - metabolism
HLA-DR3 Antigen - metabolism
Humans
Molecular Sequence Data
Recombinant Fusion Proteins - genetics
Recombinant Fusion Proteins - metabolism
Transfection
Title HLA-DO is a negative modulator of HLA-DM-mediated MHC class II peptide loading
URI https://www.ncbi.nlm.nih.gov/pubmed/9382849
https://www.proquest.com/docview/79432910
Volume 7
WOSCitedRecordID wos10.1016/s0960-9822(06)00414-3&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dS8MwED-mU_DF7-H8zIMP-hC0TZa0IMiYjg22uQeVvZU2TWSg7Vyn4H_vJd3ck_jgSymhV8rlcvmld_c7gHPOdCNMhKGeb2LKVSOhgfEU3imN_lAo6aLnzz05GASjUTiswM2iFsamVS58onPUaa7sP_IrS2Tm4952O3mntmeUja3OG2isQJUhkLEJXXK0jCHgUcJFKhGjU8tSt6zfuSp-Bi-uxaXlnOKU_Y4x3V7T3vrfV27D5hxjkmZpFDtQ0dkurJddJ7_2YNDpNendAxkXJCaZfnHU3-QtT20nr3xKckPcE33qykoQkpJ-p0WUxdmk2yUTmwiTavKau_z7fXhq3z-2OnTeVoEqFvAZTVMZM4NASwpc38JL7LxwFfqeMTwNtQySsJEGyigmjGZK4J6O85ZIqVDOKL8Gq1me6QMggZaeQjEc1ogEeCKFwLdb3jptEsbrcLZQU4Rma2MRcabzjyJaKKoOtVLT0aRk14hChodAHh7-KXoEG45L1uWWHEPV4HrVJ7CmPmfjYnrqjAGvg2H_G8DpvD0
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=HLA-DO+is+a+negative+modulator+of+HLA-DM-mediated+MHC+class+II+peptide+loading&rft.jtitle=Current+biology&rft.au=van+Ham%2C+S+M&rft.au=Tjin%2C+E+P&rft.au=Lillemeier%2C+B+F&rft.au=Gr%C3%BCneberg%2C+U&rft.date=1997-12-01&rft.issn=0960-9822&rft.volume=7&rft.issue=12&rft.spage=950&rft_id=info:doi/10.1016%2Fs0960-9822%2806%2900414-3&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0960-9822&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0960-9822&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0960-9822&client=summon